Autolus Therapeutics (AUTL) Reports Q4 Loss of $0.52
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vineti Reports Strategic Partnership with Autolus Therapeutics (AUTL) to Support Delivery of Novel-T Cell Therapies
February 25, 2019 6:25 AM ESTVineti Inc, the leading software platform of record for personalized therapeutics, today announced a new partnership to help advance and scale Autolus Therapeutics plc (NASDAQ: AUTL)s broad clinical stage pipeline of cancer treatments for hematological and solid tumors.
Autolus, a clinical-stage global biopharmaceutical company developing next-generation programmed T cell therapies, has four clinical programs in five hematological and one solid tumor indication. Vineti provides the leading software platform... More
